Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Delayed graft function in kidney transplantation.

Norberto Perico1, Dario Cattaneo, Mohamed H Sayegh

  • 1Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo-Mario Negri Institute for Pharmacological Research, Bergamo, Italy. perico@marionegri.it

Lancet (London, England)
|November 16, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A real-world implementation study of a TDM-guided dalbavancin model for bone and joint infections (101 Dalbatians).

JAC-antimicrobial resistance·2026
Same author

Effects of Fluoxetine on Cognitive Functioning in Children with Down Syndrome: A Prospective Open-Label Exploratory Study of Safety and Efficacy.

Journal of child and adolescent psychopharmacology·2026
Same author

Amoxicillin bone penetration in patients with medication-related osteonecrosis of the jaw: A preliminary study.

International journal of antimicrobial agents·2026
Same author

Seminal plasma concentrations of long-acting cabotegravir in men receiving HIV pre-exposure prophylaxis.

Antimicrobial agents and chemotherapy·2026
Same author

Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review.

Antibiotics (Basel, Switzerland)·2026
Same author

Cefepime and New Cefepime/Beta-Lactamase Inhibitor Combination for the Treatment of Gram-Negative Bacteria: Chemical Structure and Mechanism of Action, Microbiological Target, Clinical Use and PK/PD Characteristics.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Delayed graft function, a type of acute kidney injury post-transplant, impacts survival. Strategies to prevent this condition involve donor management, organ preservation, and recipient care, with new drugs showing promise.

Area of Science:

  • Nephrology
  • Transplantation Immunology
  • Renal Pathophysiology

Background:

  • Delayed graft function (DGF) is acute renal failure post-transplantation, leading to complications like oliguria, increased immunogenicity, and reduced long-term survival.
  • DGF pathogenesis involves donor-related factors and recipient-specific issues (prerenal, renal, postrenal).
  • Ischemia and reperfusion injury in preserved kidneys activate inflammatory cascades, sustaining damage and contributing to DGF.

Purpose of the Study:

  • To review the pathophysiology of renal ischemia-reperfusion injury in the context of DGF.
  • To explore current and emerging strategies for preventing and treating DGF.
  • To discuss the future directions in managing DGF, including combination therapies.

Main Methods:

Related Experiment Videos

  • Review of experimental studies and clinical data on DGF.
  • Analysis of factors contributing to DGF, including ischemia-reperfusion injury.
  • Evaluation of preventative and therapeutic strategies, including pharmacological agents.

    • Main Results:

    • Understanding the pathophysiology of ischemia-reperfusion injury has informed strategies to reduce DGF rates.
    • Current strategies focus on donor management, organ procurement/preservation, recipient fluid management, and pharmacological interventions.
    • While animal studies show promise for new drugs, clinical trials are needed; combination therapies may be necessary.

    Conclusions:

    • Elucidating renal ischemia-reperfusion injury mechanisms is key to mitigating DGF.
    • Multifaceted approaches, including improved organ preservation and targeted therapies, are crucial for reducing DGF.
    • Future research should focus on clinical validation of novel agents and combination therapies to improve transplant outcomes.